High performance thin layer chromatographic determination of atazanavir and ritonavir in combined tablet dosage form

A new simple High Performance Thin Layer Chromatographic (HPTLC) method for determination of Atazanavir and Ritonavir in combined tablet dosage form has been developed and validated. The mobile phase selected was Toluene: Ethyl acetate: Methanol (6: 4.5: 0.6, v/v/v) with UV detection at 240 nm. The retention factor for Atazanavir and Ritonavir were found to be 0.25 ± 0.004 and 0.41 ± 0.004. The method was validated with respect to linearity, accuracy, precision and robustness as per the International Conference on Harmonisation (ICH) guidelines. Results found to be linear in the concentration range of 1000-8000 ng/band for Atazanavir and 500-4000 ng/band for Ritonavir respectively. The method has been successfully applied for the analysis of drugs in pharmaceutical formulation. The % assay (Mean ± S.D.) was found to be 100. 40 ± 0.96 for Ritonavir and 99.59 ± 1.10 for Atazanavir. The method can be used for routine analysis of these drugs in combined tablet dosage forms in quality-control laboratories

Author(s): Vasudha B. Pisal, Padmanabh B. Deshpande and Ashish Gaikwad, Sujith S. Nair

Abstract | PDF

Share This Article